Show simple item record

dc.contributor.authorSánchez-Rodríguez, Estefania
dc.contributor.authorBiel-Glesson, Sara
dc.contributor.authorFernandez-Navarro, Jose R.
dc.contributor.authorCalleja, Miguel A.
dc.contributor.authorEspejo-Calvo, Juan A.
dc.contributor.authorGil Extremera, Blas 
dc.contributor.authorde la Torre, Rafael
dc.contributor.authorFito, Montserrat
dc.contributor.authorCovas, María Isabel
dc.contributor.authorVilchez, Pedro
dc.contributor.authorAlche, Juan de Dios
dc.contributor.authorMartínez De Victoria Muñoz, Emilio 
dc.contributor.authorGil Hernández, Ángel 
dc.contributor.authorMesa, Maria D.
dc.date.accessioned2019-05-10T12:19:43Z
dc.date.available2019-05-10T12:19:43Z
dc.date.issued2019-03-06
dc.identifier.citationSanchez-Rodriguez, E. [et al.]. Effects of Virgin Olive Oils Differing in Their Bioactive Compound Contents on Biomarkers of Oxidative Stress and Inflammation in Healthy Adults: A Randomized Double-Blind Controlled Trial. Nutrients 2019, 11, 561; doi:10.3390/nu11030561.es_ES
dc.identifier.issn2072-6643
dc.identifier.urihttp://hdl.handle.net/10481/55686
dc.description.abstractA regular consumption of virgin olive oil (VOO) is associated with a reduced risk of cardiovascular disease. We aimed to assess whether the raw intake of an optimized VOO (OVOO, 490 ppm of phenolic compounds and 86 ppm of triterpenes), and a functional olive oil (FOO, 487 ppm of phenolic compounds and enriched with 389 ppm of triterpenes) supplementation (30 mL per day) during three weeks would provide additional health benefits to those produced by a standard VOO (124 ppm of phenolic compounds and 86 ppm of triterpenes) on oxidative and inflammatory biomarkers. Fifty-one healthy adults participated in a randomized, crossover, and controlled study. Urinary 8-hidroxy-2’-deoxyguanosine, plasma interleukin-8 (IL-8), and tumor necrosis factor α (TNF-α) concentrations were lower after the intervention with the FOO than after the OVOO (ρ = 0.033, ρ = 0.011 and ρ= 0.020, respectively). In addition, IL-8 was lower after the intervention with FOO than after VOO intervention (ρ= 0.002). This study provides a first level of evidence on the in vivo health benefits of olive oil triterpenes (oleanolic and maslinic acids) in healthy humans, decreasing DNA oxidation and plasma inflammatory biomarkers. The trial was registered in ClinicalTrials.gov ID: NCT02520739.es_ES
dc.description.sponsorshipThe “NUTRAOLEUM Study” has been supported by the grant ITC-20131031 from the I+D FEDER-INTERCONNECTA (CDTI) and Junta de Andalucía, Spain. We thank ACER CAMPESTRES S.L., SAN FRANCISCO DE ASIS Coop. And., and AGROINSUR S.L., for the funding provided. We appreciate the support received from the workers of the clinical trials unit of the “Virgen de las Nieves” and “San Cecilio” hospitals by finding subjects for the study and for their involvement in the intervention; we thank Laura Campaña Martín, Maria Victoria Martín Laguna and Mª Cruz Rico Prados who carried out technical work, sample preparation and biomarker analyses, and Llenalia Garcia Fernández, who supervised the statistical analysis.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectOlive oil es_ES
dc.subjectVirgin olive oiles_ES
dc.subjectTriterpeneses_ES
dc.subjectPhenolic compoundses_ES
dc.subjectCardiovascular diseaseses_ES
dc.subjectMaslinic acides_ES
dc.subjectOleanolic acides_ES
dc.subjectOxidative stress es_ES
dc.subject8-hidroxy-20-deoxyguanosinees_ES
dc.subjectTNF-alphaes_ES
dc.subjectInterleukin-8es_ES
dc.titleEffects of Virgin Olive Oils Differing in Their Bioactive Compound Contents on Biomarkers of Oxidative Stress and Inflammation in Healthy Adults: A Randomized Double-Blind Controlled Triales_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución 3.0 España
Except where otherwise noted, this item's license is described as Atribución 3.0 España